2023-03-15 08:33:16 ET
- Royalty Pharma ( NASDAQ: RPRX ) said on Wednesday that it is raising its 2023 guidance after having received a $475M accelerated milestone payment from Pfizer.
- The payment follows an approval by the U.S. Food and Drug Administration of the company's Zavzpret product.
- The product provides another important new treatment option for migraine patients.
- Royalty Pharma is raising its FY23 adjusted cash receipts guidance to between $2.85B and $2.95B from the previous guidance of between $2.38B and $2.5B.
- RPRX shares were trading +0.57% pre-market.
- Source: Press Release
For further details see:
Royalty Pharma raises guidance after receiving Pfizer payment